Allogene Therapeutics, Inc. Accrued Investment Income Receivable
Allogene Therapeutics, Inc. (ALLO) had Accrued Investment Income Receivable of $2.34 million as of 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Balance Sheet › Assets
us-gaap:AccruedInvestmentIncomeReceivable · last filed 2019-11-05
- 2019-09-30: Accrued Investment Income Receivable $2.34M.
- 2019-06-30: Accrued Investment Income Receivable $3.29M.
- 2019-03-31: Accrued Investment Income Receivable $3.39M.
- 2018-12-31: Accrued Investment Income Receivable $3.11M.
| Period end | Accrued Investment Income Receivable |
|---|---|
| 2019-09-30 | $2.34M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $3.29M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $3.39M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $3.11M 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |